Inhibrx Biosciences, Inc. 8-K

What Happened
Inhibrx Biosciences, Inc. (INBX) issued a press release on May 14, 2026 announcing its financial results for the three months ended March 31, 2026. The company furnished that press release as Exhibit 99.1 to a Form 8-K under Item 2.02 (Results of Operations and Financial Condition).

Key Details

• Filing date: May 14, 2026 (Form 8-K).
• Reporting period: three months ended March 31, 2026 (Q1 2026).
• Exhibit furnished: 99.1 (press release); 104 (cover page interactive XBRL).
• Form signed by Kelly Deck, Chief Financial Officer, on behalf of Inhibrx Biosciences.

Why It Matters
This 8-K provides the company’s official quarterly results disclosure for Q1 2026; investors should review the furnished press release for specific figures (revenue, net loss, cash position, and any operational or program updates) that can affect valuation and near-term outlook. Because the press release is furnished (not filed), it is being provided for information under Item 2.02 of the Exchange Act.